---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010044"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:45:46.131141+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Azenta buys Barkey for €80M; expands cell & gene therapy cold-chain products

## Summary
- Purchase price approx €80M (~$86M) for Barkey, a provider of controlled-rate thawing devices.
- Barkey reported ~€17M in revenue for the twelve months ended March 31, 2022.
- Deal expected to close early July 2022; Barkey's owners and COO to join Azenta.
- Acquisition expected accretive to non-GAAP earnings immediately and GAAP within first year.
- Extends Azenta's cold-chain portfolio into cell & gene therapy, serving over 100 CGT customers.

## SEC filing metadata
- accession: 0001558370-22-010044
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000155837022010044/0001558370-22-010044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000155837022010044/azta-20220607x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010044
- JSON: https://secwatch.observer/filing/0001558370-22-010044.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.